A retrospective cohort study investigated the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Targeted therapies for HER2-negative advanced breast cancer include: PARP inhibitors like olaparib (Lynparza) and talazoparib (Talzenna). These drugs stop a protein known as poly-ADP ribose ...

after treatment your cancer has responded well to a type of chemotherapy called platinum chemotherapy Olaparib is only for women who have a change in a gene called BRCA1 or BRCA2. Whether you can have ...